Cat. #154163
LNCaP: ARF876L cell line
Cat. #: 154163
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: Northern Institute For Cancer Research, Newcastle University
Tool Details
*FOR RESEARCH USE ONLY
- Name: LNCaP: ARF876L cell line
- Alternate name: AR, Dihydrotestosterone Receptor, Nuclear Receptor Subfamily 3 Group C Member 4, NR3C4, DHTR
- Tool sub type: Continuous
- Parental cell: LNCaP
- Organism: Human
- Disease: Cancer
- Model: Tumour line
- Conditional: No
- Description: LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old Caucasian male in 1977. The androgen receptor (AR) in LNCaP cells harbours a T877A mutations which enables the anti-androgen flutamide to act as an agonist. This cell line is the most commonly used for prostate cancer research. In approximately 30% CRPC, AR mutations are detected and are likely selected for under pressure by hormonal therapies....
- Production details: HEK 293T cells were transfected with pLenti-FLAG-ARF876L to generate viral particles. Using a multiplicity of infection of 0.3 and 0.1, LNCaP cells were transduced with virus. Stable expressing clones were selected with 10ÄÂ??g/ml blasticidin. Ectopic AR expression was determined by western blot.
Target Details
- Target: Androgen Receptor
Handling
- Format: Frozen
- Growth medium: RPMI-1640 + 10% FBS
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice